Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 7:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 485 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo: Sterile Saline Clear all
Completed Phase 2Phase 3 Interventional

A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation

NCT05357690
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Stellate ganglion block, Bupivacaine, Placebo
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 22, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

NCT06143046
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
0 Years to 40 Years
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
22
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 22, 2026, 7:29 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine

NCT00777257
View directory record Official record
Conditions
Meningitis, Meningococcemia, Pertussis, Tetanus, Diphtheria
Interventions
T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
11 Years to 17 Years
Enrollment
1,345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
20
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Boulder, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 22, 2026, 7:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About Whether BAY H006689 Causes an Allergic Reaction When Applied as a Topical Gel in Healthy Participants

NCT06415019
View directory record Official record
Conditions
Pain, Healthy Volunteers
Interventions
Naproxen (BAYH006689), Placebo Gel, A solution of 0.9% Saline
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 22, 2026, 7:29 PM EDT
Active, not recruiting Phase 3 Interventional Results available

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT04153149
View directory record Official record
Conditions
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions
Vutrisiran, Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
17
States / cities
La Mesa, California • Los Angeles, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 22, 2026, 7:29 PM EDT
Recruiting Phase 1Phase 2 Interventional

Stem Cells for Erectile Dysfunction Post RALP

NCT07048314
View directory record Official record
Conditions
Erectile Dysfunction, Prostate Cancer
Interventions
Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office, Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR, Placebo in the OR, Placebo in clinic
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
40 Years to 70 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 22, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Pulmozyme in Infants With Cystic Fibrosis

NCT00179998
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Recombinant Human DNase (Pulmozyme), Placebos
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Month to 30 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 22, 2026, 7:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PENG Block for Arthroscopic Hip Surgery

NCT04508504
View directory record Official record
Conditions
Postoperative Pain, Hip Arthroscopy
Interventions
Preop PENG block, Placebo block, Ropivacaine 0.5% Injectable Solution, Normal Saline
Procedure · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 22, 2026, 7:29 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS

NCT05938036
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS)
Interventions
ALT-100 mAb, ALT-100 (Placebo)
Drug
Lead sponsor
Aqualung Therapeutics Corp.
Industry
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 22, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

NCT04832971
View directory record Official record
Conditions
Mixed Dyslipidemia
Interventions
ARO-ANG3, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Huntington Park, California • Hialeah, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 22, 2026, 7:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

NCT02743455
View directory record Official record
Conditions
Yellow Fever, Yellow Fever Immunisation
Interventions
ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 22, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

NCT02760407
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w, Placebo q2w
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
64
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 22, 2026, 7:29 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019
View directory record Official record
Conditions
Familial Hypercholesterolemia - Heterozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 22, 2026, 7:29 PM EDT
Not yet recruiting Phase 4 Interventional

Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)

NCT07721922
View directory record Official record
Conditions
COPD Exacerbation
Interventions
Revefenacin, formoterol fumarate, Placebo (Sterile Normal Saline), Albuterol sulfate, Ipratropium Bromide
Drug · Other
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 7:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

NCT04920786
View directory record Official record
Conditions
Alzheimer Disease
Interventions
TB006, Sterile saline (Placebo)
Drug · Other
Lead sponsor
TrueBinding, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 22, 2026, 7:29 PM EDT
Completed Not applicable Interventional Results available

Perioperative Systemic Acetaminophen to Improve Postoperative Quality of Recovery After Ambulatory Breast Surgery

NCT01852955
View directory record Official record
Conditions
Pain
Interventions
IV acetaminophen, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 22, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia

NCT04652726
View directory record Official record
Conditions
Familial Hypercholesterolemia - Heterozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Tucson, Arizona • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 22, 2026, 7:29 PM EDT
Recruiting Not applicable Interventional

Sternotomy PIFB Block in Open Heart Surgery

NCT06233318
View directory record Official record
Conditions
Autonomic Nerve Block
Interventions
Pecto-intercostal Fascial Block with 20 ml of 0.35% ropivacaine, Pecto-intercostal Fascial Block with normal saline
Procedure
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 22, 2026, 7:29 PM EDT
Not yet recruiting Early Phase 1 Interventional

hCG Treatment for Rehabilitation From a TBI

NCT07557615
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Ovidrel, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 7:29 PM EDT
Suspended Phase 3 Interventional Accepts healthy volunteers

The Effects of Sex Hormones and Alcohol on Sleep

NCT06143059
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Ethanol, Saline
Drug
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 45 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

NCT03339713
View directory record Official record
Conditions
Healthy
Interventions
Ad26.RSV.preF, Fluarix, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 22, 2026, 7:29 PM EDT
Recruiting Phase 2 Interventional

Twin Block, Pain Medications and Third Molar Extractions

NCT04880707
View directory record Official record
Conditions
Acute Pain
Interventions
Twin block local anesthetic nerve block using standard dental anesthetic, Twin block with placebo
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 22, 2026, 7:29 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions

NCT04540900
View directory record Official record
Conditions
Skin Roughness, Wrinkle, Fine Lines, Skin Thickness
Interventions
KB301, Placebo
Biological · Other
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2029
U.S. locations
4
States / cities
Campbell, California • Newport Beach, California • Rancho Santa Margarita, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 22, 2026, 7:29 PM EDT
Completed Not applicable Interventional Results available

Aerosolized Albuterol Use in Severe BPD

NCT02766673
View directory record Official record
Conditions
Severe Bronchopulmonary Dysplasia
Interventions
Albuterol Sulfate, Sterile Saline
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 1 Year
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 22, 2026, 7:29 PM EDT